Astria Therapeutics Stock Price, News & Analysis (NASDAQ:ATXS) $4.75 +0.10 (+2.15%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$4.51▼$4.8050-Day Range$4.42▼$8.3852-Week Range$4.26▼$16.28Volume310,194 shsAverage Volume193,350 shsMarket Capitalization$172.43 millionP/E RatioN/ADividend YieldN/APrice Target$19.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Astria Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside315.8% Upside$19.75 Price TargetShort InterestHealthy1.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.35Based on 2 Articles This WeekInsider TradingAcquiring Shares$7 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.28) to ($2.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsMedical Sector143rd out of 951 stocksPharmaceutical Preparations Industry51st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAstria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.75, Astria Therapeutics has a forecasted upside of 315.8% from its current price of $4.75.Amount of Analyst CoverageAstria Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.99% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Astria Therapeutics has recently decreased by 12.97%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAstria Therapeutics does not currently pay a dividend.Dividend GrowthAstria Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATXS. Previous Next 3.0 News and Social Media Coverage News SentimentAstria Therapeutics has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Astria Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for ATXS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Astria Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,995,698.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Astria Therapeutics is held by insiders.Percentage Held by Institutions87.85% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Astria Therapeutics are expected to grow in the coming year, from ($2.28) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Astria Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Astria Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAstria Therapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Astria Therapeutics Stock (NASDAQ:ATXS)Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.Read More ATXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXS Stock News HeadlinesNovember 27, 2023 | finance.yahoo.comAstria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy CongressNovember 24, 2023 | benzinga.comAstria Therapeutics Stock (NASDAQ:ATXS) Earnings Dates and Earning CallsDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 21, 2023 | finance.yahoo.comAstria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx ConferenceNovember 16, 2023 | benzinga.comAstria Therapeutics Stock (NASDAQ:ATXS), Analyst Ratings, Price Targets, PredictionsNovember 14, 2023 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | finance.yahoo.comAstria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate DevelopmentsNovember 13, 2023 | finance.yahoo.comAstria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate UpdateDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 12, 2023 | businesswire.comAstria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 ...November 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Trevi Therapeutics (TRVI)November 10, 2023 | markets.businessinsider.comAstria Therapeutics Presents Potential For STAR-0125 To Prevent HAENovember 10, 2023 | benzinga.comEarnings Preview For Astria TherapeuticsNovember 10, 2023 | finance.yahoo.comIs a Surprise Coming for Astria Therapeutics (ATXS) This Earnings Season?November 10, 2023 | finance.yahoo.comAstria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific MeetingNovember 3, 2023 | finance.yahoo.comAstria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific MeetingOctober 30, 2023 | finance.yahoo.comAstria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13thOctober 19, 2023 | benzinga.comAstria Therapeutics Director Trades $7.00M In Company StockOctober 15, 2023 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 60% of the companyOctober 13, 2023 | markets.businessinsider.comExpert Ratings for Astria TherapeuticsOctober 13, 2023 | markets.businessinsider.comBuy Rating for Astria Therapeutics: Promising Acquisition and Strategic Development Plan for STAR-0310October 13, 2023 | msn.comHC Wainwright & Co. Maintains Astria Therapeutics (ATXS) Buy RecommendationOctober 12, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Astria Therapeutics: Here's What You Need To KnowOctober 12, 2023 | markets.businessinsider.comAstria Therapeutics’ Promising Disruptions: Buy Rating Justified by Novel Therapies and Strategic AcquisitionsOctober 11, 2023 | markets.businessinsider.comAstria Enters Into Licensing Deal With Ichnos Sciences For Atopic Dermatitis TreatmentOctober 11, 2023 | finance.yahoo.comAstria Therapeutics Announces Pricing of $64 Million Underwritten OfferingOctober 11, 2023 | msn.comAstria signs licensing deal with Ichnos Sciences to develop atopic dermatitis treatmentSee More Headlines Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATXS CUSIPN/A CIK1454789 Webwww.catabasis.com Phone(617) 349-1971Fax617-273-2637Employees45Year Founded2008Price Target and Rating Average Stock Price Target$19.75 High Stock Price Target$25.00 Low Stock Price Target$18.00 Potential Upside/Downside+315.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.33% Return on Assets-25.77% Debt Debt-to-Equity RatioN/A Current Ratio20.41 Quick Ratio20.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book1.93Miscellaneous Outstanding Shares36,300,000Free Float35,062,000Market Cap$172.43 million OptionableNot Optionable Beta0.84 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Jill C. Milne Ph.D. (Age 55)Co-Founder, CEO, President & Director Comp: $928.52kMr. Benjamin S. Harshbarger J.D. (Age 54)Chief Legal Officer Comp: $621.91kMr. Noah Clauser CPA (Age 49)CFO & Treasurer Comp: $508.79kMs. Keri McGrailSenior Vice President of Human ResourcesMs. Andrea L. MatthewsChief Business OfficerMr. Andrew A. Komjathy (Age 59)Chief Commercial Officer Dr. Christopher J. Morabito M.D. (Age 53)Chief Medical Officer Mr. John RueschSenior Vice President of Pharmaceutical Sciences & Technical OperationsMore ExecutivesKey CompetitorsSelecta BiosciencesNASDAQ:RNACAltimmuneNASDAQ:ALTPDS BiotechnologyNASDAQ:PDSBTheseus PharmaceuticalsNASDAQ:THRXImmutepNASDAQ:IMMPView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 3,422 shares on 11/24/2023Ownership: 0.059%Walleye Capital LLCBought 19,530 shares on 11/21/2023Ownership: 0.070%Jacobs Levy Equity Management Inc.Bought 31,856 shares on 11/17/2023Ownership: 0.576%Affinity Asset Advisors LLCBought 349,425 shares on 11/15/2023Ownership: 3.567%AQR Capital Management LLCBought 12,790 shares on 11/15/2023Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions ATXS Stock Analysis - Frequently Asked Questions Should I buy or sell Astria Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATXS shares. View ATXS analyst ratings or view top-rated stocks. What is Astria Therapeutics' stock price target for 2024? 4 Wall Street research analysts have issued 1 year target prices for Astria Therapeutics' shares. Their ATXS share price targets range from $18.00 to $25.00. On average, they predict the company's stock price to reach $19.75 in the next twelve months. This suggests a possible upside of 315.8% from the stock's current price. View analysts price targets for ATXS or view top-rated stocks among Wall Street analysts. How have ATXS shares performed in 2023? Astria Therapeutics' stock was trading at $14.89 at the start of the year. Since then, ATXS shares have decreased by 68.1% and is now trading at $4.75. View the best growth stocks for 2023 here. When is Astria Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our ATXS earnings forecast. How were Astria Therapeutics' earnings last quarter? Astria Therapeutics, Inc. (NASDAQ:ATXS) posted its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.31. During the same quarter in the prior year, the company posted ($3.36) earnings per share. When did Astria Therapeutics' stock split? Shares of Astria Therapeutics reverse split on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. Who are Astria Therapeutics' major shareholders? Astria Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (9.15%), Affinity Asset Advisors LLC (3.57%), Jacobs Levy Equity Management Inc. (0.58%), Stratos Wealth Partners LTD. (0.15%), Connor Clark & Lunn Investment Management Ltd. (0.15%) and Invesco Ltd. (0.09%). Insiders that own company stock include Andrew Komjathy and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Astria Therapeutics? Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ATXS) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.